 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial termination, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Jul 23, 2024
P1, N=140, Terminated, Sponsor: Merck Sharp & Dohme LLC
Completed --> Terminated; Business Reasons
- ||| Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Jan 25, 2023
P1, N=140, Completed, Sponsor: Merck Sharp & Dohme LLC
Completed --> Terminated; Business Reasons Active, not recruiting --> Completed
- || Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Nov 18, 2022
P1, N=160, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Active, not recruiting --> Completed Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023
- || Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Jun 30, 2022
P1, N=160, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023 Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> May 2023 | Trial primary completion date: Oct 2022 --> May 2023
- || Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Mar 3, 2022
P1, N=160, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> May 2023 | Trial primary completion date: Oct 2022 --> May 2023 Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022
- | Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Mar 31, 2020
P1, N=135, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jun 2022 --> Oct 2022 | Trial primary completion date: Jun 2022 --> Oct 2022 Trial completion date: Feb 2021 --> Apr 2022 | Trial primary completion date: Feb 2021 --> Apr 2022
- | Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Jan 21, 2020
P1, N=135, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Feb 2021 --> Apr 2022 | Trial primary completion date: Feb 2021 --> Apr 2022 Trial completion date: Jul 2020 --> Feb 2021 | Trial primary completion date: Jul 2020 --> Feb 2021
- | Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Jul 30, 2019
P1, N=135, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Jul 2020 --> Feb 2021 | Trial primary completion date: Jul 2020 --> Feb 2021 Trial completion date: Oct 2021 --> Jul 2020 | Trial primary completion date: Oct 2021 --> Jul 2020
- || Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Enrollment change, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Apr 24, 2018
P1, N=110, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Oct 2021 --> Jul 2020 | Trial primary completion date: Oct 2021 --> Jul 2020 N=66 --> 110
- || Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Feb 8, 2018
P1, N=66, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=66 --> 110 Trial primary completion date: Sep 2019 --> Oct 2021 | Trial completion date: Sep 2019 --> Oct 2021
- ||| Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
Enrollment open, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Sep 28, 2017
P1, N=66, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2019 --> Oct 2021 | Trial completion date: Sep 2019 --> Oct 2021 Not yet recruiting --> Recruiting
- ||| Keytruda (pembrolizumab) / Merck (MSD), MK-2118 / Merck (MSD)
New P1 trial, Monotherapy, Metastases: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (clinicaltrials.gov) - Aug 15, 2017
P1, N=66, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.